Empagliflozin for obesity

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 20 Dec 2024: Trial registered, NCT06745063
  2. 30 May 2025: Trial started, NCT06745063

The trials

NCT06745063: Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity

State
Under way
Phase
Phase 2
People
50 planned
Started
30 May 2025
Primary completion
31 Dec 2028
Arms
Empagliflozin
Results
None posted
  1. 20 Dec 2024: Trial registered
  2. 30 May 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as Empagliflozin 10 MG, Empagliflozin 10 MG OD, Empagliflozin 25 MG, Empagliflozin10Mg Tab, Glyxambi component empagliflozin, Jardiance, Trijardy xr component empagliflozin.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.